Expert review of hematology · 2026
Leukapheresis versus no leukapheresis for hyperleukocytosis in acute myeloid leukemia: an updated systematic review and meta-analysis of early mortality.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Reyes Jamiel, Reyes Alexander
Аннотация
INTRODUCTION: Leukapheresis is used for rapid cytoreduction in adults with acute myeloid leukemia (AML) and hyperleukocytosis, but its effect on early mortality remains uncertain. We performed an updated systematic review and meta-analysis of comparative studies.
METHODS: MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching were searched from inception to March 2026. Comparative studies of leukapheresis versus no leukapheresis in adults with AML and hyperleukocytosis were included. Risk of bias was assessed using ROBINS-I, and certainty of evidence was assessed using GRADE. Random-effects meta-analysis of crude 2 × 2 data was performed using odds ratios (ORs).
RESULTS: Thirteen retrospective comparative studies were included; 10 studies comprising 1,406 patients contributed to the primary 30-day mortality analysis. Leukapheresis was not clearly associated with lower 30-day mortality compared with no leukapheresis (OR 0.94, 95% CI 0.65-1.34; I2 = 0.0%). Only one study reported an adjusted estimate. Most studies were at serious risk of bias, and certainty of evidence was very low.
CONCLUSIONS: Current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis. Confounding 3by indication remains a major limitation.
REGISTRATION: This study was prospectively registered on PROSPERO (identifier: CRD420261351743).
METHODS: MEDLINE, CENTRAL, ClinicalTrials.gov, Google Scholar, and citation searching were searched from inception to March 2026. Comparative studies of leukapheresis versus no leukapheresis in adults with AML and hyperleukocytosis were included. Risk of bias was assessed using ROBINS-I, and certainty of evidence was assessed using GRADE. Random-effects meta-analysis of crude 2 × 2 data was performed using odds ratios (ORs).
RESULTS: Thirteen retrospective comparative studies were included; 10 studies comprising 1,406 patients contributed to the primary 30-day mortality analysis. Leukapheresis was not clearly associated with lower 30-day mortality compared with no leukapheresis (OR 0.94, 95% CI 0.65-1.34; I2 = 0.0%). Only one study reported an adjusted estimate. Most studies were at serious risk of bias, and certainty of evidence was very low.
CONCLUSIONS: Current non-randomized evidence does not establish a reliable early-mortality benefit of leukapheresis. Confounding 3by indication remains a major limitation.
REGISTRATION: This study was prospectively registered on PROSPERO (identifier: CRD420261351743).